Ironwood Pharmaceuticals Initiates Phase II Clinical Trial of sGC Stimulator IW-1701 in Patients with Sickle Cell Disease
Sickle cell disease is a debilitating genetic disorder that causes red blood cells to become sickle-shaped, reducing normal red blood cell number, blood flow and oxygen delivery to organs. Many of the symptoms of sickle cell disease are believed to be caused by a deficiency of nitric oxide (NO), an important regulator of blood flow and inflammatory processes. IW-1701 has been shown to improve NO signaling in non-clinical studies, and is being investigated for its potential to treat multiple aspects of sickle cell disease pathophysiology, including red blood cell sickling, decreased blood flow and vascular inflammation.
“There is a considerable unmet need in sickle cell disease, and patients
with this condition would benefit from innovative treatments that not
only prevent painful crises, organ damage and other serious
complications, but also address underlying causes of these symptoms,”
STRONG-SCD is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging Phase II clinical trial designed to assess the safety and tolerability of oral, once-daily IW-1701 in patients with sickle cell disease. Additional exploratory objectives include the evaluation of the pharmacokinetic profile of IW-1701 as well as its effects on sickle cell disease symptoms, health-related quality of life and biomarkers of pharmacodynamic activity. The trial is expected to enroll approximately 88 patients between 16 and 70 years of age. Patients will remain on their existing treatment regimens throughout the trial. After a two-week single-blind placebo run-in period, patients will be randomized to receive placebo or one of three dose levels of IW-1701 administered for approximately 12 weeks.
Ironwood recently presented IW-1701 data at the 2017
About Sickle Cell Disease
Sickle cell disease is an inherited red blood cell disorder that causes red blood cells to deform into a sickle shape, impacting blood flow to organs and tissues. These sickled red blood cells are more susceptible to hemolysis (rupturing). Upon red blood cell rupturing, nitric oxide (NO) is depleted due to arginase release and hemoglobin scavenging. NO is an important regulator of blood flow, and the resulting deficiency of NO is believed to contribute to disease mechanisms and symptoms of sickle cell disease.
A life-long disease, sickle cell disease affects an estimated 100,000 Americans and millions of people throughout the world. Patients with sickle cell disease can experience various complications, including attacks of severe pain called pain crises, chronic pain, acute chest syndrome, pulmonary hypertension, ankle ulcers, renal complications and an increased risk of serious infections. Severe symptoms may include strokes and pulmonary complications, which can be fatal.
IW-1701, an investigational soluble guanylate cyclase (sGC) stimulator discovered and wholly-owned by Ironwood, is being studied in patients with sickle cell disease and in patients with achalasia. IW-1701 has been shown in non-clinical studies to modulate the nitric oxide/soluble guanylate cyclase/cyclic guanosine monophosphate (NO/sGC/cGMP) signaling pathway, which is believed to be implicated in achalasia and sickle cell disease. Currently in Phase II development for sickle cell disease and for achalasia, IW-1701 has the potential to address the underlying causes of these diseases by improving NO signaling and thereby increasing the second messenger cGMP.
About Ironwood’s sGC Program
As a pioneering expert in cyclic GMP (cGMP), Ironwood is building on its success with linaclotide, which stimulates guanylate cyclase-C in the intestine, to develop a pipeline of soluble guanylate cyclase (sGC) stimulators. sGC plays an important role in regulating diverse physiological processes; dysregulation of sGC may play a role in multiple serious diseases. Ironwood’s sGC stimulators are believed to harness the nitric oxide (NO)/sGC/cGMP pathway by working synergistically with NO to improve blood flow and metabolism and decrease inflammation and fibrosis.
Ironwood is advancing IW-1973, its lead sGC stimulator, for the potential treatment of diabetic nephropathy and of heart failure with preserved ejection fraction (HFpEF). Ironwood’s second clinical sGC stimulator, IW-1701, is being developed for the potential treatment of achalasia and of sickle cell disease. In addition, Ironwood has a pipeline of other sGC stimulators in pre-clinical development.
This press release contains forward-looking statements. Investors are
cautioned not to place undue reliance on these forward-looking
statements, including statements about Ironwood’s sGC program and the
clinical program for IW-1701, including the design, size, scope and
potential results of the Phase II clinical trial; the mechanism of
action of IW-1701; the size of the potential patient population; the
data to be generated from the Phase II clinical trial; the timing that
these data are expected to be available; the cause of the disease and
the symptoms suffered by the potential patient population; and IW-1701
as a potential treatment for sickle cell disease. Each
forward‐looking statement is subject to risks and uncertainties that
could cause actual results to differ materially from those expressed or
implied in such statement. Applicable risks and uncertainties include
those related to the risk that we are unable to enroll as many patients
in the clinical study or complete the Phase II clinical trial on the
same timeline as we currently anticipate; the risk that the data from
the clinical trial may not be available when we currently anticipate
them or do not demonstrate the results we expect, including with respect
to efficacy, safety and tolerability; the risk that the Phase II
clinical trial needs to be discontinued for any reason, including
safety, enrollment, manufacturing or economic reasons; the patient
population is not as large as we presently estimate; the effectiveness
of development and commercialization efforts by us and our partners;
preclinical and clinical development, manufacturing and formulation
development; the risk that findings from our completed nonclinical and
clinical studies may not be replicated in later studies; decisions by
regulatory authorities; the risk that we may never get sufficient patent
protection for IW-1701 or that we are not able to successfully protect
such patents; the outcomes in legal proceedings to protect or enforce
the patents relating to IW-1701; developments in the intellectual
property landscape; challenges from and rights of competitors or
potential competitors; the risk that our planned investments do not have
the anticipated effect on our business or the IW-1701 program; and those
risks listed under the heading "Risk Factors" and elsewhere in
Ironwood's Quarterly Report on Form 10-Q for the quarter ended
Investor and Media Relations
|"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding Ironwood Pharmaceuticals's business which are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's Annual Report or Form 10-K for the most recently ended fiscal year.|
|MEDIA & INVESTOR RELATIONS CONTACT|